Angiogenesis is essential for tumor growth and blocking this process might be a valid tool for the control of cancer growth. We showed previously that tumor angiogenesis in integrin a1-null mice is reduced compared to that of wild type animals and that over-expression of matrix metalloproteinase 9 (MMP-9) in the a1-null and consequent generation of angiostatin (an inhibitor of endothelial cell growth) from circulating plasminogen was implicated in the mechanism of tumor inhibition. Our ®ndings suggested that secretion of excess MMPs generates inhibitors of endothelial cell proliferation, including but not necessarily limited to angiostatin, resulting ultimately in auto-inhibition of angiogenesis. Thus MMP inhibitors used as anti-tumor drugs might in fact cause a paradoxical increase in tumor angiogenesis and tumor growth. In order to determine whether MMP-9 expression was directly involved in the regulation of tumor growth, we speci®cally inhibited or enhanced MMP-9 synthesis in vitro and in vivo, and subsequently analysed primary endothelial cell proliferation and angiostatin synthesis, as well as tumor vascularization and development. We provide evidence that reduction of plasma levels of MMP-9 in either normal or integrin a1-null mice leads to decreased synthesis of angiostatin and consequent increased tumor growth and vascularization. In contrast, speci®cally enhancing MMP-9 expression in vivo caused a reduction in tumor vascularization. These ®ndings are the opposite to other studies suggesting a pro-tumorigenic role for MMP-9, and may account for some of the recently observed failures of anti MMP therapy in tumor treatment.
Introduction
Matrix metalloproteinases (MMPs) are proteolytic enzymes involved in the degradation of extracellular matrix components. They play a role in both physiological and pathological processes such as tissue remodeling, wound healing, angiogenesis, and tumor growth and metastasis (Forget et al., 1999) . During tumor angiogenesis dierent cell types contribute to the synthesis of MMPs including tumor and endothelial cells. Synthesis of MMPs by endothelial cells can play opposite eects on tumor angiogenesis, facilitating extracellular matrix degradation and new blood vessel formation (Hiraoka et al., 1998) , but also blocking angiogenesis by producing inhibitors of endothelial cell growth, including angiostatin (Cornelius et al., 1998; Kleiner and Stetler-Stevenson, 1999; Sang, 1998) . We have previously shown that in integrin a1-null mice tumor angiogenesis is markedly reduced compared with that of wild-type animals. This reduction is due to over-expression of gelatinase B (MMP-9) in the a1-null and consequent generation of endothelial inhibitor angiostatin from circulating plasminogen (Pozzi et al., 2000) . Increased MMP synthesis in the a1-null mouse seems to be related to a de®ciency in the activation of the Ras/Shc/MAPK pathway (Pozzi et al., 1998) , and thus unchecked activation of an integrin a2-p38-MMP cascade (Ravanti et al., 1999) . In this context we have shown that activation of MAPK via a1 integrin, besides promoting cell survival and proliferation on collagenous substrata (Pozzi et al., 1998) , is an inhibitory pathway for both collagen and MMP synthesis (Gardner et al., 1999) .
The integrin a1 null mouse, a genetic model for regulated but increased MMP synthesis and angiostatin generation, suggests that use of MMP inhibitors in treating tumor growth may have the unwanted eect of preventing angiostatin production and thus increasing tumor angiogenesis and growth. In this context, it has been reported that patients with small cell lung cancer receiving the MMP inhibitor Tanomastat (BAY12-9566) did worse than controls (Bayer, Corp., 1999) , and treatment with the gelatinase inhibitor Prinomastat in patients with non small cell lung cancer did not lead to any bene®cial eect as compared to the placebo group (Agouron, 2000) . Finally, in vivo treatment with Batimastat resulted in increased liver metastases of breast carcinoma and T-cell lymphoma in nude or syngeneic mice (Kruger et al., 2001) .
To determine whether we could decrease mouse plasma MMP-9/angiostatin levels and consequently increase tumor growth and development, we tested doxycycline as an inhibitor of MMPs both in vitro and in vivo. Doxycycline belongs to the family of chemically modi®ed tetracyclines, which can suppress MMP activity in a variety of tissues and tumors (Sipos et al., 1994) , as well as inhibit gelatinase activity in human breast carcinoma cells (Fife and Sledge, 1995) . Although doxycycline has been considered a nonselective MMP inhibitor, published data suggest that this chemically modi®ed tetracycline seems to preferentially inhibit gelatinase B/MMP9 activity and expression in corneal epithelial (Sobrin et al., 2000) and human endothelial cells (Hanemaaijer et al., 1998) , as well as reducing in vivo levels of MMP-9 in tissues from patients with thoracic aneurysms (Curci et al., 2000) . These observations prompted us to analyse the eect of doxycycline on MMP synthesis and consequent tumor vascularization in normal and a1-null mice. In vivo treatment with doxycycline reduced plasma levels of MMP-9 with consequent decreased angiostatin generation, and increased tumor vascularization and growth, in both normal and integrin a1-null mice. In contrast, speci®c enhancement of MMP-9 levels in vitro and in vivo caused a reduction in endothelial cell growth and tumor vascularization respectively.
Results

Doxycycline rescues endothelial cell proliferation in vitro
Integrin a1-null mice are a unique model for increased endothelial MMP-9 synthesis and consequent increased angiostatin levels, causing auto-inhibition of endothelial cell proliferation both in vitro and in vivo (Pozzi et al., 2000) . For this reason we compared the proliferation of wild type and a1-null mouse lung microvascular endothelial cells grown in the presence of dierent concentrations of doxycycline. Doxycycline in the culture medium caused an increase of a1-null endothelial cell proliferation to wild type levels (Figure 1a) , while no signi®cant eect was observed on wild type endothelial cell proliferation, consistent with our ®nding that wild type endothelial cells make no detectable MMP-9 in vitro (Pozzi et al., 2000) . Maximum rescue of a1-null endothelial cell proliferation was observed at 10 mM doxycycline and persisted at 50 mM. At these concentrations doxycycline has been shown to decrease MMP-9 protein and RNA levels in human endothelial cells (Hanemaaijer et al., 1998) .
Reduced tumor growth and vascularization in a1-null hosts is independent of mouse strain or tumor line but dependent on increased MMP/angiostatin plasma levels To determine whether decreased tumor vascularization recently described in integrin a1-null mice (Pozzi et al., 2000) was independent of the mouse strain and tumor cell line, we introduced the integrin a1 targeted mutation into the Balb/c background. This allowed us to analyse tumor growth and vascularization of two dierent tumor lines, namely colon (CT26) and renal (RENCA) carcinoma cells known to generate primary tumors in the Balb/c background (Sayers et al., 1998; Xiang et al., 1998) . Subcutaneous tumors were initiated with 5610 5 CT26 or 3610 5 RENCA cells and permitted to grow for 14 days before harvest. Balb/c a1-null mice developed smaller (Figure 1b,c) and less vascularized tumors (Figure 2e ± g) than their wild type counterparts, similar to a1-null 129Sv/Jae mice (Pozzi et al., 2000) . Plasma levels of MMP-9 in CT26-( Figure  2a ,b) or RENCA-(not shown) tumor-bearing Balb/c a1-null mice were threefold greater than those observed in tumor bearing wild type animals, and also similar to 129Sv/Jae a1-null mice (Pozzi et al., 2000) . In contrast, no changes in plasma levels of MMP-2 were observed between the two genotypes ( Figure 2a) . Similarly, in CT26- (Figure 2c ,d) and RENCA-(not shown) tumor-bearing a1-null Balb/c mice plasma angiostatin was twofold higher than in tumor bearing wild type animals. Thus reduced tumor growth and vascularization in a1-null hosts is independent of mouse strain or tumor line, but correlates with increased MMP-9 and subsequent angiostatin generation.
The observation that doxycycline rescues endothelial cell proliferation in vitro (Figure 1a ) prompted us to analyse the eect of this chemically modi®ed tetracycline on tumor growth and development in vivo. To determine whether preventing MMP-9 and consequent angiostatin generation resulted in increased tumor growth and development, wild type and a1-null mice were treated with 40 or 80 mg/kg/day doxycycline in the drinking water (Fife and Sledge, 1998) from the time of tumor cell injection. In contrast to the situation in vitro, wild type tumor hosts do make appreciable plasma MMP-9 and angiostatin, although less than the a1-null animals (Pozzi et al., 2000) . Plasma levels of MMP-9 were signi®cantly reduced by doxycycline in both CT26-tumor-bearing wild type and a1-null animals, with maximum reduction observed in mice receiving 80 mg/kg/day doxycycline (Figure 2a,b) . This doxycycline-mediated eect appeared to be speci®c for plasma MMP-9, as no changes in plasma levels of MMP-2 were observed after treatment with this chemically modi®ed tetracycline (Figure 2a) . Similar results were observed with plasma from RENCA-and p60.5-tumor bearing wild type and a1-null mice (not shown). Both CT26-and RENCA-tumor bearing wild type and a1-null mice receiving doxycycline developed bigger (Figure 1b ,c) and more vascularized tumors (Figure 2e ± g) compared to those of their untreated counterparts. Similar results were observed using 129Sv/Jae mice injected with p60.5 cells (not shown). As expected, treatment with doxycycline also caused a signi®cant reduction in plasma angiostatin levels in both wild type and a1-null CT26-tumor bearing mice (Figure 2c,d) , as well as in RENCA-and p60.5-tumor bearing mice (not shown).
To determine whether treatment with doxycycline mainly aected the MMP/angiostatin axis, and not the expression of other angiogenic-related factors we determined the plasma levels of VEGF, b-FGF and TGF-b in CT26-tumor bearing mice untreated or treated with doxycycline. Similar plasma levels of VEGF, b-FGF and TGF-b were observed between CT26-tumor bearing wild type and integrin a1-null mice and no signi®cant changes were observed between the two genotypes after treatment with doxycycline (Table 1) . Thus in vivo treatment with doxycycline leads to decreased levels of plasma MMP-9 and angiostatin, and consequent increased tumor vascularization and growth.
Increased MMP-9 synthesis leads to reduced endothelial cell proliferation in vitro and decreased tumor vascularization and growth in vivo
Our results indicate that blocking MMP-9 expression and consequent angiostatin synthesis cause increased tumor vascularization and growth and this eect is independent of the strain or genotype of mice. To determine whether the presence of exogenous MMP-9 could inhibit endothelial cell proliferation, we examined proliferation of wild type and a1-null primary endothelial cells grown in the presence of 5% FCS and dierent concentrations of human MMP-9 (gift of J Quigley, TSRI). In the presence of this metalloproteinase both wild type and a1-null endothelial cells showed a signi®cant reduction in proliferation ( Figure  3a ,b) that is most likely due to increased generation of angiostatin from the plasminogen present in FCS, as previously shown (Pozzi et al., 2000) . Co-addition of anti-human MMP-9 antibody (gift of J Quigley) (Ramos-DeSimone et al., 1993) 5 RENCA (c) cells and the total tumor volume for each mouse was determined at 14 days post injections as previously described (Pozzi et al., 2000) . Bars and errors indicate the mean and standard deviation (5 animal/genotype were analysed for each treatment). Tumors grown in a1-null mice are signi®cantly smaller than those grown in their wild type counterparts (`Control') (P50.05). a1-null mice treated with 40 (`Dox-40') or 80 (`Dox-80') mg/kg/day doxycycline show a signi®cant increase in tumor volume compared to the control group (`Control') (**=P50.05). Similarly wild type mice treated with both 40 and 80 (b, CT26 cells) or 80 (c, RENCA cells) mg/kg/day doxycycline show signi®cant increased tumor volume compared to their untreated counterparts (*=P50.05) Plasma levels of VEGF, b-FGF and TGF-b were measured by a commercially available microtiter-based sandwich enzyme immunoassay system as described in Materials and methods. The numbers indicate the mean and standard deviation of three plasma samples derived CT26-tumor bearing wild type and integrin a1-null mice untreated (`Control') or treated with 40 and 80 mg/kg/day doxycycline (`Dox-40' and`Dox-80'). Similar levels of plasma VEGF, b-FGF and TGF-b were observed between CT26-tumorbearing wild type and integrin a1-null mice. No signi®cant changes were observed between the two genotypes following treatment with doxycycline
In order to enhance MMP-9 expression in vivo we took advantage of the fact that CT26 tumor cells do not express zymographically detectable levels of MMP-9 (Figure 3c ). We generated a stably transfected polyclonal CT26-tumor cell line expressing high levels of human recombinant MMP-9 (CT26-hMMP9) (Figure 3c) (Bernhard et al., 1994) . Although pro-hMMP9 was evident after 12 h of incubation (Figure 3c , left panel), the active form of hMMP-9 was detected only in the medium of CT26-hMMP9 after 48 h of incubation (Figure 3c , right panel). For this reason 48-h conditioned medium from CT26 and CT26-hMMP9 was then tested for its capability to inhibit endothelial cell proliferation. Wild type endothelial cells incubated in the presence of medium from CT26-hMMP9 containing 5% serum (used as a source of plasminogen) showed a signi®cant reduction in proliferation compared to endothelial cells incubated with medium from CT26 cells transfected with vector only or normal endothelial complete culture medium (Figure 3d ).
To evaluate the eect of increased MMP-9 in vivo, we determined tumor growth and vascularization in wild type Balb/c mice injected with CT26 or CT26-hMMP9 cells. Increased levels of MMP-9 were observed in plasma from CT26-hMMP9-tumor bearing wild type mice when compared to plasma from CT26-tumor bearing animals (Figure 4a,b) , whereas no changes in MMP-2 levels were observed ( Figure  4a ). To determine whether the increased MMP-9 level in plasma from CT26-hMMP9-tumor bearing mice was indeed due to synthesis and secretion of hMMP-9 by stable transfected tumor cells, plasma derived from CT26 and CT26-hMMP9 tumor bearing mice was run on a 4% SDS ± PAGE containing gelatin to allow a better separation between mouse and human MMP9 (Figure 4e ). While mouse MMP-9 was visible in plasma derived from both CT26-and CT26-hMMP9-tumor bearing wild type mice, human MMP-9 was detected only in plasma derived from CT26-hMMP9-tumor bearing wild type mice ( Figure  4e ). Increased MMP-9 plasma levels in CT26-hMMP9 tumor bearing wild type mice resulted in increased synthesis of angiostatin from circulating plasminogen as compared to that observed in plasma from CT26-tumor bearing animals (Figure 4c,d) . Consistent with this ®nding, CT26-hMMP9 derived tumors were smaller and less vascularized (CD31 staining, not shown) than CT26 derived tumors in wild type mice (Figure 5a,b) , and similar in appearance to CT26-tumors in a1-null mice. To determine whether we could reverse the eect of increased MMP-9 secretion by CT26-hMMP9 tumors, we also treated these tumor-bearing animals with doxycycline. Treatment with 40 and 80 mg/kg/day doxycycline caused a reduction only in levels of plasma MMP-9 ( Figure  4a ,b) as well as angiostatin (Figure 4c,d ) and resulted in bigger and more vascularized tumors in both CT26 and CT26-hMMP9 tumor bearing wild type mice (Figure 5a,b) , thus con®rming that the growth reduction in CT26-hMMP9 tumors was due to their increased expression and vascular release of MMP-9, and not due to an irrelevant cloning or transfection eect.
Discussion
In this study we have shown that reducing plasma levels of MMP-9 causes decreased generation of the endothelial inhibitor angiostatin with a subsequent increase of tumor vascularization and growth. While we have previously shown that angiostatin generation is necessary for the endothelial inhibition caused by MMP-9 in vitro, it is possible that other known or unknown MMP-9 targets may also be relevant in vivo. Our results support the paradigm that secretion of excess MMPs by endothelial cells promotes autoinhibition of angiogenesis by generating angiostatin and possibly other protein fragments (Cornelius et al., 1998; Kleiner and Stetler-Stevenson, 1999; Sang, 1998) . This is in striking contrast to the generally perceived role of MMPs being pro-tumorigenic, and that blockade of MMP expression or activity should inhibit tumor growth. Given this apparent incongruity, the rationale of MMP inhibitor function and the studies that support it need to be examined.
Firstly, inhibition of MMP release by the tumor may reduce extracellular matrix degradation and tumor invasiveness and thus block growth or metastasis. Many studies show the importance of MMPs and other proteases in tumor cell invasion in vitro (Fife and Sledge, 1995; Lokeshwar, 1999; Seftor et al., 1998) and it has been shown, for example, that mice treated orally with tetracyclines developed a reduced number of lung metastases following injection of melanoma cells via tail vein inoculation (Seftor et al., 1998) . However it is not completely understood if the reduced number of metastases is due to a direct eect of tetracyclines on MMP synthesis or on tumor cell proliferation. In this context studies on chemically modi®ed tetracycline type inhibitors on MMPs have shown that while MMPs can indeed be directly inhibited at the levels of transcription (Curci et al., 2000; Hanemaaijer et al., 1998) and function (Smith et al., 1999; Sorsa et al., 1998) , many tumor and normal cell lines show a tetracycline-mediated growth inhibition which may be independent of the MMP blockade (Bettany and Wolowacz, 1998; Sledge, 1995, 1998; van den Bogert et al., 1985) . This might explain the observation that doxycycline, administered at 20 mg/kg/day, signi®cantly inhibited tumor growth of mammary carcinoma cells subcutaneously injected in athymic mice (Fife and Sledge, 1998) . In contrast, doxycycline at 20 mg/kg/day in vivo had no signi®cant eects on tumor growth or plasma MMP-9 levels in our study (not shown).
Secondly, MMPs such as MT1-MMP (Hiraoka et al., 1998; Sipos et al., 1994) , MMP-2 and MMP-9 appear to be important in early events in angiogenesis itself, and thus blockade of MMPs should block tumor angiogenesis. It has been shown that culturing microvascular endothelial cells on collagen substrata in the presence of Oncogene MMP9/angiostatin axis and tumor angiogenesis A Pozzi et al Figure 2 (a) Gelatin zymogram of plasma from CT26-tumor bearing wild type and a1-null mice. Plasma, obtained from untreated or doxycycline-treated mice, was analysed for MMP-2 and MMP-9 levels by zymography as previously described (Pozzi et al., 2000) . No changes in MMP-2 levels were observed in the plasma derived from tumor-bearing wild type and integrin a1-null mice untreated (`Control') or treated with doxycycline (`Dox-40' and`Dox-80'). In contrast, increased levels of MMP-9 were observed in the plasma from CT26-tumor-bearing a1-null mice relative to their wild type counterparts (`Control'). Plasma derived from CT26-tumor-bearing wild type and a1-null mice treated with doxycycline (`Dox-40' and`Dox-80') showed reduced levels of MMP-9 relative to the untreated group (`Control'). (b) MMP-9 bands shown in (a) were quanti®ed by densitometry and expressed as arbitrary units. Bars and errors indicate the mean and standard deviation of MMP-9 expression of plasma obtained from three mice per each group. Signi®cant reduction of MMP-9 levels was observed in both CT26-tumor-bearing wild type and a1-null mice treated with doxycycline (`Dox-40' and`Dox-80') (P50.05). (c) Western blot of plasma angiostatin in CT26-tumor-bearing wild type and a1-null mice. Increased levels of angiostatin (40 ± 45 kDa), detected by Western blot as previously described (Pozzi et al., 2000) , were observed in CT26-tumor-bearing a1-null mice relative to the wild type samples (`Control'). Plasma derived from CT26-tumorbearing wild type and a1-null mice treated with doxycycline (`Dox-40' and`Dox-80') showed reduced levels of plasma angiostatin relative to the untreated group (`Control'). (d) Angiostatin bands shown in (c) were quanti®ed by densitometry and expressed as arbitrary units. Note the direct correlation between MMP-9 expression (a,b) and plasma levels of angiostatin within genotypes and synthetic inhibitors of MMPs results in inhibition of cell migration, dierentiation and formation of capillarylike tubes (Jia et al., 2000) , indicating that MMPmediated collagen degradation plays an important role during the initiation of angiogenesis. In addition Brooks et al. (1998) have shown that PEX, a non-catalytic fragment of MMP-2, reduced retinal neo-vascularization by preventing the binding of MMP-2 to integrin avb3 on the cell surface of sprouting cells and consequent extracellular matrix degradation. Furthermore, homozygous mice with a null mutation in the gelatinase B gene exhibit an abnormal pattern of skeletal plate vascularization and ossi®cation (Vu et al., 1998) . As transplantation of wild type bone marrow groups (c,d) . (e,f) Tumor vascularity of tumors from wild type and a1-null mice untreated or treated with dierent concentrations of doxycycline. Tumors from wild type and a1-null mice were stained with anti CD31 antibody and tumor vascularity measured by the extent of CD31 positive structures as described (Pozzi et al., 2000) . Bars and errors indicate the mean and standard deviation (eight tumors/genotype were examined for each treatment). Tumors from a1-null mice injected with CT26 (e) or RENCA (f) cells show reduced vascularity compared to those grown in their wild type counterparts (`Control') (P50.05). Tumors derived from a1-null mice treated with doxycycline (`Dox-40' and`Dox-80') show signi®cantly increased tumor vascularity compared to their untreated counterparts (`Control') (**P50.05). Similarly wild-type mice treated with 40 (e, CT26 cells) or 80 (f, RENCA cells) mg/kg/day doxycycline show signi®cantly increased tumor vascularity compared to their untreated counterparts (*P50.05). (g) Frozen sections of tumors from wild type and integrin a1-null mice injected with CT26 cells were stained with anti-CD31 antibody. Tumors from a1-null mice are less vascularized compared to those grown in their wild type counterparts (`Control'). Treatment with doxycycline (`Dox-40' and`Dox-80') resulted in increased tumor vascularity in both genotypes Figure 3 (a,b) Eect of MMP-9 on endothelial cell proliferation. Wild type (a) and a1-null (b) endothelial cells were plated as described in Figure 1a in the presence of dierent concentrations of human MMP-9. The Y axis indicates absolute c.p.m. incorporation of primary endothelial cells grown as described in Figure 1a . Dots and errors indicate the mean and standard deviations of triplicate samples of endothelial cells from wild type (a) and a1-null (b) mice. The presence of MMP-9 (*) at the concentrations indicated signi®cantly inhibited wild type and a1-null endothelial cell proliferation (P50.05). Co-addition of anti-MMP-9 antibody (open circles) (7-11C IgG) at 10 mg/ml rescued endothelial cell growth (P50.05). (c) Conditioned medium from CT-26 tumor cells untransfected (7) or stably transfected as a bulk transfection with human MMP-9 (+) was analysed by gelatin zymography to evaluate MMP expression. While abundant MMP-2 was detected in the conditioned medium of both untransfected (7) and transfected (+) tumor cells, MMP-9 expression was evident only in the conditioned medium from tumor cells stably transfected with hMMP-9 (+). While the pre-active form of hMMP-9 was visible after 12 h of incubation, the active form of hMMP-9 became evident only after 48 h of incubation. (d) Eect of conditioned medium from CT-26 tumor cells on endothelial cell proliferation. Wild type endothelial cells were plated as described in Figure 1a in the presence of EGM-2-MV (`clonetics'), or 48-h conditioned medium from CT26 cells untransfected (`mock') or stably transfected with human MMP-9 (`hMMP-9'). The Y axis indicates absolute c.p.m. incorporation of primary endothelial cells grown as described in Figure 1a . Dots and errors indicate the mean and standard deviations of triplicate samples. Conditioned medium from CT26 stable transfected with human MMP-9 signi®cantly inhibited endothelial cell growth compared to the control group (`Clonetics') (P50.05) Figure 4 (a) Gelatin zymogram of plasma from CT26-and CT26-hMMP9-tumor bearing wild type mice. Samples were prepared as described in Figure 2a . No changes in MMP-2 levels were observed in the plasma from CT26-and CT26-hMMP9-tumor bearing mice untreated (`Control') or treated with doxycycline (`Dox 40' and`Dox 80'). In contrast, increased levels of MMP-9 were observed in CT26-hMMP9-tumor-bearing samples relative to those derived from CT-26-tumor bearing mice (`Control'). Treatment with Doxycycline (`Dox 40' and`Dox 80') signi®cantly reduced plasma levels of MMP-9 in both CT26-and CT26-hMMP9-tumorbearing wild type mice compared to untreated group (`Control'). (b) MMP-9 bands shown in a were quanti®ed as described in Figure 2 . Bars and errors indicate the mean and the higher number from the two bands of MMP-9 per each group. (c) Western blot of plasma angiostatin in CT26-and CT26-hMMP9-tumor-bearing wild type mice. Increased levels of angiostatin (K1-3), detected by Western blot as previously described (Pozzi et al., 2000) , were observed in CT26-hMMP9-tumor-bearing wild type mice relative to those derived from CT-26-tumor bearing mice (`Control'). Treatment with Doxycycline (`Dox 40' and`Dox 80') signi®cantly reduced plasma levels of angiostatin in both CT26-and CT26-hMMP9-tumor-bearing wild type mice compared to untreated group (`Control'). (d) Angiostatin bands shown in (c) were quanti®ed as described in Figure 2d . Bars and errors indicate the mean and the higher number from the two bands of angiostatin per each group. (e) Plasma from CT26-and CT26-hMMP9-tumor bearing wild type mice was run of a 4% SDS ± PAGE containing gelatin in order to separate mouse and human MMP9. While a band comigrating with puri®ed mouse MMP-9 (m) was visible in plasma derived from both CT26-and CT26-hMMP9-tumor-bearing wild type mice, a band co-migrating with puri®ed human MMP-9 (h) was visible only in plasma derived from CT26-hMMP9-tumorbearing wild type mice Figure 5 Volume and vascularity of tumors grown for 14 days from four quadratic bolus injections of 5610 5 CT26 untransfected (CT26) or stably transfected with hMMP-9 (CT26-hMMP9) in the subcutis of Balb/c wild type mice. Total tumor volume (a) and vascularity (b) in CT26 and CT26-hMMP9-tumor bearing wild-type mice untreated or treated with dierent concentrations of doxycycline were determined as described in Figure 1 . Bars and errors indicate the mean and standard deviation [5 animals/genotype (a) or 8 tumors/genotype (b) were analysed for each treatment]. Tumors grown from CT26-hMMP9 cells are signi®cantly smaller and less vascularized than those grown from their untransfected counterparts (`Control') (P50.05). CT26-hMMP9-tumor-bearing mice treated with 40 (`Dox-40') or 80 (`Dox-80') mg/kg/day doxycycline show a signi®cant increased tumor volume as well as vascularity compared to the control group (`Control') (**=P50.05). Similarly CT26-tumor-bearing wild type mice treated with 80 mg/kg/day doxycycline show signi®cant increased tumor volume and vascularity compared to their untreated counterparts (*=P50.05) cells rescues vascularization in gelatinase B-null growth plates, this study suggests that vascularization is a process mediated by MMP-9 (Vu et al., 1998) . MMP-9 has been also described as an angiogenic switch that activates the quiescent vasculature by promoting release of VEGF (Bergers et al., 2000) . Altogether, these results clearly suggest that MMPs can promote angiogenesis and that absolute lack of MMP activity can prevent new blood vessel formation, but they do not address any relationship between higher levels of MMP activity and control of endothelial cell proliferation, which is the subject of the present study. There is no reason to believe that the pro-and anti-angiogenic eects exerted by MMPs are mutually exclusive possibilities. It is possible that low levels of MMPs are necessary to promote angiogenesis by facilitating endothelial cell migration or activation and/or release of angiogenic factors, whereas high levels of MMPs might contribute in reducing endothelial cell growth by directly generating endothelial cell inhibitors including angiostatin (Pozzi et al., 2000) .
In this study we have shown that plasma levels of MMP-9 control endothelial cell proliferation and tumor vascularization, and that in vitro this activity is dependent on angiostatin generation from plasminogen, while in vivo there is a correlation between angiostatin and MMP9 levels. It is possible that other cleavage products inhibitory to cell growth, for example collagen fragments, might also be generated by MMP-9 in vivo. Regardless of the intermediary, inhibition of MMP-9 results in increased tumor vascularization and growth, and vice versa.
In conclusion, our results not only seem to provide an explanation for the recently observed failures of anti MMP therapy in tumor treatment, but also suggest that while MMP inhibitors might be successfully used in the prophylaxis of potentially metastatic cancers, they may also have the potential to exacerbate the growth of established tumors by preventing the generation of inhibitors of endothelial cell growth.
Materials and methods
Primary tumor growth
All experiments were performed according to institutional animal care guide-lines. Four to 6-month old 129Sv/Jae male or Balb/c wild type and a1-null mice were given four dorsal subcutaneous injections of syngeneic tumor cell lines as previously described (Pozzi et al., 2000) . Brie¯y, tumors were initiated with 10 5 p60.5 cells (Soloway et al., 1996) , which are tumorigenic in the 129 Sv/Jae host; or 5610 5 colon tumor cells (CT26) (Xiang et al., 1998) or 3610 5 renal carcinoma cells (RENCA) (Sayers et al., 1998) , which generate primary tumors in the Balb/c background. In some experiments tumor-bearing wild type and a1-null mice were treated with 40 or 80 mg/kg/day doxycycline (Sigma) in the drinking water (Fife and Sledge, 1998) from the time of tumor cell injection. As we determined that the daily water uptake for a 20 g mouse is approximately 2 ml, doxycycline was added to the drinking water at the concentration of 0.4 or 0.8 mg/ml.
Tumors were permitted to grow for 10 ± 14 days before harvest. Tumor volume was measured with a caliper and expressed as total tumor volume (cm 3 )/mouse. Tumors were then frozen for histology.
Doxycycline determination in plasma
Plasma levels of doxycycline were detected by HPLC as previously described (Axisa et al., 2000) with the following modi®cations. Five hundred ml plasma from untreated or doxycycline-treated mice (six mice/group) were spiked with 1 mg of oxytetracycline (internal standard) and ®ltered through an Oasis HLB extraction cartridge (Waters Associates) (Axisa et al., 2000) . Chemically modi®ed tetracyclines were eluted from the cartridge with 500 ml 50% acetonitrile in water. Samples were then lyophilized, suspended in 200 ml water and injected into a mBondapak tm C18 column (Waters Associates) equilibrated with 10% acetonitrile and 0.1% H 3 PO 4 in water. Elution was performed using 70% acetonitrile and 0.1% H 3 PO 4 in water as mobile phase. The system was calibrated by preparing solutions of oxycycline (5 mg/ml constant concentration) and doxycycline ranging from 0.5 ± 25 mg/ml. Samples were detected at 350 nm. The steady state plasma levels of doxycycline in mice treated for 14 days with 40 and 80 mg/kg/day doxycycline was 2.3+1.02 and 4.5+1.5 mg/ml, respectively.
Immunostaining and quantification
Seven-micrometer tumor frozen sections were stained with the anti-mouse CD31 (PECAM-1) (Pharmingen) and Vactastain ABC and counterstained with hematoxylin. Sections were then imaged and processed as previously described (Pozzi et al., 2000) . Brie¯y, sections, with labels coded to blind the observer, were imaged with a digital camera (Pixera, Los Gatos, CA, USA) and the images were processed by using Scion Image software (Frederick, MD, USA). Each color image was split into red, green and blue components, and image math performed to generate and image of (BlueRed) 6 (Green) 6 0.01, which was smoothed twice to remove single pixels of density. The image was then thresholded and CD-31 positive structures bigger than ®ve pixels were automatically counted in each section and their areas were measured. Tumor vascularity was expressed as percentage of area occupied by CD-31 positive structures per microscopic ®eld.
Transfection
CT26 cells were transfected with a human MMP-9 expression construct (human MMP-9 cDNA inserted into the pRC/RSV eukaryotic expression vector, gift of Dr R Mushel, University of Pennsylvania, Philadelphia, PA, USA) (Bernhard et al., 1994) using Fugene 6 transfection reagent (Roche) according to the manufacturer's instructions. Selection was begun 48 h after transfection by adding Geneticin (G418 sulfate: GIBCO) at 600 mg/ml to the medium. Stably transfected CT26 cells as a polyclonal bulk transfection (here referred as CT26-hMMP9) were maintained under selection with Geneticin at 300 mg/ml throughout all the experiments.
Zymography
Gelatin zymograms were performed as previously described (Pozzi et al., 2000) . For assay of MMP-9 secretion by tumor cells, 10 5 CT26 and CT26-hMMP9 cells were plated for 12 h onto 24-well plates in the presence of medium containing Oncogene MMP9/angiostatin axis and tumor angiogenesis A Pozzi et al 10% FCS. Cells were then washed with PBS and incubated with 300 ml of serum-free medium for 12 or 48 h. Thirty microliters of conditioned medium was loaded for zymography. For plasma MMPs, blood from untreated or doxycycline-treated mice was collected with 1/10 volume of 3 mM EDTA 0.1% sodium citrate and spun for 30 min at 1000 g. Plasma was pre-cleared with a mixture of protein A and G sepharose beads. Normalization by protein level in plasma (Micro-BCA, Pierce) was done to correct for minor (+5%) dierences in plasma dilution by anticoagulant. Thirty micrograms total proteins were loaded for zymography. MMP-9 bands were quanti®ed by densitometry using an Alpha Imager 2000 (Alpha Innotech, San Leandro, CA, USA).
Western blot
One hundred micrograms of total plasma proteins from untreated or doxycycline-treated mice were loaded on 10% SDS ± PAGE and run under non-reducing conditions (Rivas et al., 1998; Standker et al., 1997) . Gels were then transferred onto immobilon-P (Millipore) and incubated with a puri®ed mouse mAb (®nal concentration 10 mg/ml) that interact with a mouse angiostatin fragment (anti K1-3), as previously described (Pozzi et al., 2000) . The signal was visualized with a peroxidase-conjugated goat anti-mouse and ECL kit (Pierce). Angiostatin bands were quanti®ed by densitometry using an Alpha Imager 2000 (Alpha Innotech, San Leandro, CA, USA).
Proliferation assay
Primary lung microvascular endothelial cells, isolated from normal and a1-null mice as described (Pozzi et al., 2000) , were cultured in EGM-2-MV medium containing 5% FCS (Clonetics). For proliferation assays 5610 3 wild type or a1-null endothelial cells were plated in the same medium (200 ml volume) on 96-well plates coated with 20 mg/ml collagen I (Vitrogen 100) in the presence of dierent concentrations of doxycycline. In some experiments cells were grown in EGM-2-MV medium containing 5% FCS and dierent concentrations of human MMP-9 (gift of J Quigley, TSRI) in the presence or absence of 10 mg/ml antihuman MMP-9 antibody (7-11C IgG1) (gift of J Quigley, TSRI). Human MMP-9 was activated by pre-incubation with 10 mM CaCl 2 (10 ml ®nal volume) for 1 h at 378C and subsequently added to cells. 7-11C IgG1 mAbs was chosen as blocking antibody as it has been shown to react speci®cally with human MMP-9 and to inhibit its activity (Ramos-DeSimone et al., 1993) . In some experiments wild type endothelial cells were grown in media previously conditioned from CT26 and CT26-hMMP9 cells. Conditioned medium was made by growing tumor cells for 48 h in EGM-2-MV medium containing 5% FCS. At 48 h the activated form of hMMP9 was evident in the conditioned medium from CT26-hMMP9 cells (see Figure 3c , right panel). After 2 days cells were pulsed for an additional 48 h with 3 H-Thymidine (1 mCi/well). The cells were then harvested, and trichloroacetic acid-precipitated lysates were measured with a b-counter.
Enzyme immunoassay for quantitative determination of plasma growth factors
Levels of b-FGF, TGF-b and VEGF in plasma from untreated or doxycycline treated mice were measured by a commercially available microtiter-based sandwich enzyme immunoassay system (R&D Systems, Minneapolis, MN, USA) following the manufacturer's instructions. Brie¯y, 100 ± 200 ml of serial diluted samples (mouse plasma) or standards (recombinant human b-FGF, human-TFB-b or mouse VEGF) were added to each microtiter plate coated with a mouse monoclonal antibody speci®c for b-FGF, TGF-b or VEGF and then incubated for 2 h at RT. Following a wash, 100 ± 200 ml of horseradish peroxidaselinked rabbit polyclonal antibody against b-FGF, TGF-b or VEGF were added to each well and plates incubated for 2 h at RT. Following a wash, 100 ml of substrate solution (tetramethylbenzidine and hydrogen per-oxide) were added to the wells and plates incubated for 20 ± 30 min. After washing, 25 ± 50 ml of stop solution (2 N H 2 SO 4 ) were added to each well. Optimal absorbance was read at 450 nm using a Dynatech spectrophotometer.
